Literature DB >> 23798714

CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease.

James M Coghill1, Kenneth A Fowler, Michelle L West, Leshara M Fulton, Hendrik van Deventer, Karen P McKinnon, Benjamin G Vincent, Kaifeng Lin, Angela Panoskaltsis-Mortari, Donald N Cook, Bruce R Blazar, Jonathan S Serody.   

Abstract

The infusion of donor regulatory T cells (Tregs) has been used to prevent acute graft-versus-host disease (GVHD) in mice and has shown promise in phase 1 clinical trials. Previous work suggested that early Treg migration into lymphoid tissue was important for GVHD prevention. However, it is unclear how and where Tregs function longitudinally to affect GVHD. To better understand their mechanism of action, we studied 2 Treg-associated chemokine receptors in murine stem cell transplant models. CC chemokine receptor (CCR) 4 was dispensable for donor Treg function in the transplant setting. Donor Tregs lacking CCR8 (CCR8(-/-)), however, were severely impaired in their ability to prevent lethal GVHD because of increased cell death. By itself, CCR8 stimulation was unable to rescue Tregs from apoptosis. Instead, CCR8 potentiated Treg survival by promoting critical interactions with dendritic cells. In vivo, donor bone marrow-derived CD11c(+) antigen-presenting cells (APCs) were important for promoting donor Treg maintenance after transplant. In contrast, host CD11c(+) APCs appeared to be dispensable for early activation and expansion of donor Tregs. Collectively, our data indicate that a sustained donor Treg presence is critical for their beneficial properties, and that their survival depends on CCR8 and donor but not host CD11c(+) APCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798714      PMCID: PMC3731935          DOI: 10.1182/blood-2012-06-435735

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking.

Authors:  Dulce Soler; Tricia L Humphreys; Stanley M Spinola; James J Campbell
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

2.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.

Authors:  L S Taams; J Smith; M H Rustin; M Salmon; L W Poulter; A N Akbar
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

4.  T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.

Authors:  J S Serody; S E Burkett; A Panoskaltsis-Mortari; J Ng-Cashin; E McMahon; G K Matsushima; S A Lira; D N Cook; B R Blazar
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Increase of regulatory T cells in the peripheral blood of cancer patients.

Authors:  Anna Maria Wolf; Dominik Wolf; Michael Steurer; Guenther Gastl; Eberhard Gunsilius; Beatrix Grubeck-Loebenstein
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

6.  Skin-versus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells.

Authors:  Andrea Iellem; Lucia Colantonio; Daniele D'Ambrosio
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

7.  Skin-homing CLA+ T cells and regulatory CD25+ T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309.

Authors:  Lucia Colantonio; Andrea Iellem; Francesco Sinigaglia; Daniele D'Ambrosio
Journal:  Eur J Immunol       Date:  2002-12       Impact factor: 5.532

8.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

9.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

10.  Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.

Authors:  A Iellem; M Mariani; R Lang; H Recalde; P Panina-Bordignon; F Sinigaglia; D D'Ambrosio
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  22 in total

Review 1.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 2.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 3.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 4.  Chemokines and their receptors play important roles in the development of hepatocellular carcinoma.

Authors:  Chun-Min Liang; Long Chen; Heng Hu; Hui-Ying Ma; Ling-Ling Gao; Jie Qin; Cui-Ping Zhong
Journal:  World J Hepatol       Date:  2015-06-08

Review 5.  Mechanisms of Mixed Chimerism-Based Transplant Tolerance.

Authors:  Julien Zuber; Megan Sykes
Journal:  Trends Immunol       Date:  2017-08-18       Impact factor: 16.687

6.  CCR8+FOXp3+ Treg cells as master drivers of immune regulation.

Authors:  Yiftah Barsheshet; Gizi Wildbaum; Eran Levy; Alon Vitenshtein; Chika Akinseye; Jeremy Griggs; Sergio A Lira; Nathan Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

7.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

8.  Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.

Authors:  Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O Lightbourn; Cameron S Bader; Warren Alperstein; Norman H Altman; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-08       Impact factor: 5.742

9.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.